KRAS and non-small cell lung carcinoma: In a 2019 study by Jeanson and colleagues, NSCLC patients with G12D, G12V, and G13C KRAS mutations exhibited higher PD-L1 expression compared to patients with G12A or G12C KRAS mutations—although the clinical outcomes with immunotherapy were not significantly different between the groups (127).